1. Investigating the Economic Impacts of New Public Pharmaceutical Policies in Greece: Focusing on Price Reductions and Cost-Sharing Rates 
Siskou Ch. Olga, RN, MSc, PhD, Kaitelidou Ch. Daphne, RN, MSc, PhD, Litsa S. Panagiota, MSc, Georgiadou S. Georgia, MSc, Alexopoulou A. Helen, MSc, Paterakis G. Panagiotis, MSc, PhD, Argyri P. Sotiria, Bc, Liaropoulos L. Lycourgos, MSc, PhD 
Value in Health Regional Issues 
Volume 4, Pages (September 2014)
DOI: /j.vhri
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Distribution of consumption of therapeutic categories to various cost-sharing levels: first period vs fourth period.
Value in Health Regional Issues 2014 4, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Average price per box for each therapeutic category in euros: first period to fourth period.
Value in Health Regional Issues 2014 4, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Average monthly pharmaceutical expenditure in euros (mio): EOPYY and households. EOPYY, National Organization for Health Care Services Provision.
Value in Health Regional Issues 2014 4, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions